Clinical trial NCT06966427: Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections
Official title: Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Type 1 Diabetes
Type 2 Diabetes
Keywords: Type 1 diabetes
Type 2 diabetes
Dose guidance system
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
Collaborators: name: DreaMed Diabetes
First posted: 2025-05-11
Enrollment: 45
Sex: ALL
Minimum age (years): 6
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A prospective, randomized, single blind, two-arms, multicenter study
Primary purpose: TREATMENT

Brief summary: A prospective, randomized, single blind, two-arms, multicenter study. The study aims to assess the safety of a dosing-guided system (DGS) that provides direct advice on insulin dosing recommendations and diabetes management to individuals with diabetes using insulin or starting basal insulin therapy, guided by their continuous glucose monitoring (CGM).

The study population will include up to 45 individuals with diabetes, distributed as follows: 15 with Type 1 diabetes (T1D) and 15 with Type 2 diabetes (T2D), both on MDI therapy and 15 with T2D using or starting to use basal insulin.

The study will include a 2- to 4-week run-in period followed by a 6-week intervention period.


Eligibility criteria: Inclusion Criteria:

* Documented T1D or T2D, for at least 6 months
* Aged ≥ 6 years ≤ 75 years
* HbA1c ≤ 11%
* For Segment 1: Using basal-bolus MDI therapy, i.e. basal insulin and a bolus that is either:

  1. Carbohydrate counting with carbohydrate ratio (CR) and correction factor (CF)
  2. Fix dose for meal / meal estimation with CF
* For Segment 2: Using or prescribed basal insulin
* Participants using the following type of insulin as directed in the instructions for use:

  1. Basal insulin: Glargine (including Rezvoglar, Semglee, Toujeo, Soliqua), Degludec (including Tresiba U-100, Tresiba U-200, Xultophy), Determir
  2. Bolus insulin: regular insulin, rapid analogues (Insulin Aspart, Insulin Glulisine, Insulin Lispro) or ultra-rapid analogues (Fiasp, Lyumjev)
* Participants willing to use FreesStyle Libre CGM according to manufacturer instructions, document insulin delivery, meals, and daily activities.
* Participants have a smartphone compatible with study requirements.
* Participants are willing and able to sign a written informed consent form to use their data.
* Participants are willing to use the bolus calculator for insulin dosing (only for segment 1)

Exclusion Criteria:

1. Concomitant diseases/treatment that influence metabolic control or any significant diseases/conditions including psychiatric disorders and substance abuse or drug or alcohol abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patients' safety.
2. Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus, such as:

   1. Subject has unstable or rapidly progressive renal disease or has eGFR \< 45 or is receiving dialysis
   2. Subject has active proliferative retinopathy
   3. Active gastroparesis
3. Participation in any other interventional study
4. Female participant who is pregnant or planning to become pregnant within the planned study duration
5. Individuals who are using one of the following types of insulin:

   1. Intermediate-acting insulin (NPH)
   2. Mixed insulin like:

   i. Premix NPH/ Regular (e.g. Humalin 70/30, Novolog 70/30) ii. Premix analogs (e.g, Novolog mix 70/30, Hu,alog mix 75, 25, Humalog Mix 50/50) c. Inhale insulin (e.g. Afrezza)
6. Hypoglycemia unawareness
7. Individuals who are treated with intravenous (IV) insulin injections, or a combination of insulin injections and/or IV insulin and insulin pump therapy.
8. Individuals who have extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements.
9. An episode of diabetic keto-acidosis within the month prior to study entry and/or severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrolment.

Primary outcomes:
measure: Sensor glucose percentage of time in hypoglycemia below 54 mg/dL
timeFrame: Aafter 6 weeks of intervention period
Secondary outcomes:
measure: Number of events of glucose readings below 54 mg/dL
timeFrame: After 6 weeks of intervention period
measure: Sensor glucose percentage of time in hyperglycemia above 250 mg/dL
timeFrame: After 6 weeks of intervention period
Other outcomes:
measure: Glucose Management Indicator (GMI)
timeFrame: After 6 weeks of intervention period
measure: Percentage of glucose readings between 70- 180 mg/dl
timeFrame: After 6 weeks of intervention period
measure: Change in (Hemoglobin A1c) HbA1C post-study treatment
timeFrame: After 6 weeks of intervention period
measure: Percentage of glucose readings below 70 mg/dl
timeFrame: After 6 weeks of intervention period
measure: Mean sensor glucose
timeFrame: After 6 weeks of intervention period
measure: Glucose variability measured by Standard Deviation (SD) and CV%
timeFrame: After 6 weeks of intervention period
measure: Time to reach optimal insulin dose
timeFrame: After 6 weeks of intervention period
measure: Total insulin dose and the amount of basal and/or bolus insulin dose
timeFrame: After 6 weeks of intervention period
measure: Device satisfaction questioner
timeFrame: After 6 weeks of intervention period
Locations:
city: Petach Tikva
country: Israel
facility: Schneider Children Medical Center of Israel
city: Ljubljana
country: Slovenia
facility: University Medical Center of Ljubljana
Study officials:
affiliation: Schneider Children's Medical Center
name: Moshe Phillip, MD
role: PRINCIPAL_INVESTIGATOR
References: